Brokerages Expect Intec Pharma Ltd (NASDAQ:NTEC) Will Post Earnings of -$0.28 Per Share
Analysts forecast that Intec Pharma Ltd (NASDAQ:NTEC) will report ($0.28) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Intec Pharma’s earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.25). Intec Pharma posted earnings of ($0.34) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 17.6%. The business is scheduled to issue its next quarterly earnings report on Wednesday, August 21st.
On average, analysts expect that Intec Pharma will report full year earnings of ($1.05) per share for the current year, with EPS estimates ranging from ($1.15) to ($0.98). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.85) per share, with EPS estimates ranging from ($1.03) to ($0.67). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that cover Intec Pharma.
Intec Pharma (NASDAQ:NTEC) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.05.
NASDAQ NTEC traded down $0.40 during trading hours on Monday, hitting $2.99. The company had a trading volume of 382,045 shares, compared to its average volume of 433,203. Intec Pharma has a fifty-two week low of $2.99 and a fifty-two week high of $9.25. The business has a fifty day moving average of $4.35. The company has a market cap of $98.16 million, a price-to-earnings ratio of -2.14 and a beta of 0.28.
Several institutional investors and hedge funds have recently modified their holdings of the company. Knott David M increased its holdings in shares of Intec Pharma by 2.5% during the first quarter. Knott David M now owns 290,434 shares of the biotechnology company’s stock valued at $2,129,000 after purchasing an additional 6,961 shares during the period. BlackRock Inc. acquired a new position in shares of Intec Pharma during the fourth quarter valued at $67,000. Marshall Wace North America L.P. acquired a new position in shares of Intec Pharma during the first quarter valued at $117,000. Delek Group Ltd. acquired a new position in shares of Intec Pharma during the first quarter valued at $154,000. Finally, Sigma Planning Corp acquired a new position in shares of Intec Pharma during the first quarter valued at $183,000. 33.64% of the stock is currently owned by institutional investors.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Featured Article: Calculating net profit and net profit margin ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.